The case history of a 4 year old girl with primary hypoparathyroidism is reported. Treatment with oral 1\g=a\-hydroxyvitaminD3 did not result in normal calcium and phosphate levels, whereas treatment with oral 1\g=a\,25-dihydroxyvitaminD3 did. During the treatment period, the patient developed signs of severe liver disease and died in a picture of increased intracranial pressure. Post-mortem examination revealed a giant cell hepatitis and severe cirrhosis. The clinical course is consistent with a liver vitamin D3 hydroxylation defect.Several clinically important diseases are associated with derangements of calcium and vitamin D meta¬ bolism. The availability of hydroxylated vitamin D metabolites has become important in treatment of such conditions (DeLuca 1982). A number of stud¬ ies (Haussler & Brickman 1982;Lund et al. 1980) has shown that the hypocalcaemia associated with hypoparathyroidism can be readily adjusted with small doses of lcx-hydroxyvitamin D3 or let,25-dihydroxyvitamin D3. The rapid turnover of these metabolites makes them preferable to vitamin D (Tojo et al. 1982).The use of vitamin D or monohydroxylated vitamin D metabolites requires renal and/or hepa¬ tic hydroxylations in the formation of the metabolically active form, lot,25-dihydroxvvitamin D